Search

Displaying results 6681 - 6690 of 10000 in total
  1. Drug

    Furaprofen

    go.drugbank.com/drugs/DB06499
    Experimental

  2. Drug

    Cutamesine

    go.drugbank.com/drugs/DB06618
    Investigational

  3. Drug

    Praconase

    go.drugbank.com/drugs/DB05584
    Investigational

  4. Drug

    Tranilast

    go.drugbank.com/drugs/DB07615
    Investigational

    Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. … Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

    Synonyms: N-(3,4-Dimethoxycinnamoyl)anthranilic acid
  5. Drug

    Tifacogin

    go.drugbank.com/drugs/DB06437
    Investigational

  6. Drug

    Rebimastat

    go.drugbank.com/drugs/DB06573
    Investigational

  7. Drug

    NVS antibody

    go.drugbank.com/drugs/DB05312
    Experimental

    This drug has been developed using Medarex's UltiMAb Human Antibody Development System to treat autoimmune diseases.

  8. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.

  9. Drug

    Becaplermin

    go.drugbank.com/drugs/DB00102
    ApprovedInvestigational

    Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds. … Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae.

  10. Drug

    Tanaproget

    go.drugbank.com/drugs/DB04787
    Experimental

    Because of this tanaproget may prove to produce fewer side effects in comparison. It is currently in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals. … An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.